Bio-Techne Corp
NASDAQ:TECH

Watchlist Manager
Bio-Techne Corp Logo
Bio-Techne Corp
NASDAQ:TECH
Watchlist
Price: 73.03 USD 0.4% Market Closed
Market Cap: 11.6B USD
Have any thoughts about
Bio-Techne Corp?
Write Note

Bio-Techne Corp
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Bio-Techne Corp
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Bio-Techne Corp
NASDAQ:TECH
Depreciation & Amortization
$111.3m
CAGR 3-Years
7%
CAGR 5-Years
7%
CAGR 10-Years
17%
Thermo Fisher Scientific Inc
NYSE:TMO
Depreciation & Amortization
$3.2B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
8%
Danaher Corp
NYSE:DHR
Depreciation & Amortization
$2.3B
CAGR 3-Years
2%
CAGR 5-Years
11%
CAGR 10-Years
10%
Mettler-Toledo International Inc
NYSE:MTD
Depreciation & Amortization
$123m
CAGR 3-Years
5%
CAGR 5-Years
7%
CAGR 10-Years
7%
Agilent Technologies Inc
NYSE:A
Depreciation & Amortization
$257m
CAGR 3-Years
-7%
CAGR 5-Years
2%
CAGR 10-Years
-4%
IQVIA Holdings Inc
NYSE:IQV
Depreciation & Amortization
$1.1B
CAGR 3-Years
-6%
CAGR 5-Years
-1%
CAGR 10-Years
25%
No Stocks Found

Bio-Techne Corp
Glance View

Market Cap
11.6B USD
Industry
Life Sciences Tools & Services
Economic Moat
None

Bio-Techne Corp. began its journey with a clear focus: to bridge the gap between biological research and practical applications, a mission that it continues to pursue with zeal. At its core, Bio-Techne operates as a pioneer in the production and distribution of biotechnology products, catering to the needs of the scientific community across the globe. The company specializes in providing essential tools for life sciences research, including proteins, antibodies, and reagents, empowering researchers to explore and innovate in fields ranging from cancer biology to neuroscience. These offerings are developed with meticulous care and a deep understanding of the scientific process, which positions Bio-Techne as a trusted ally to laboratories and research institutions worldwide. The financial heartbeat of Bio-Techne lies in its diverse portfolio, which extends into clinical diagnostics and genomics, segments that are critical in an era of personalized medicine and rapid technological advancement in healthcare. The company's revenue streams are robust, driven by a strategic blend of direct sales and collaborations with major pharmaceutical and biotech companies. Furthermore, Bio-Techne smartly leverages its acquisitions to fortify its market position, enhancing its capabilities and expanding its product lines. This agility and foresight not only enable Bio-Techne to sustain its growth trajectory but also to continually meet the ever-evolving demands of a fast-paced, innovation-driven industry.

TECH Intrinsic Value
57.79 USD
Overvaluation 21%
Intrinsic Value
Price

See Also

What is Bio-Techne Corp's Depreciation & Amortization?
Depreciation & Amortization
111.3m USD

Based on the financial report for Sep 30, 2024, Bio-Techne Corp's Depreciation & Amortization amounts to 111.3m USD.

What is Bio-Techne Corp's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
17%

Over the last year, the Depreciation & Amortization growth was 2%. The average annual Depreciation & Amortization growth rates for Bio-Techne Corp have been 7% over the past three years , 7% over the past five years , and 17% over the past ten years .

Back to Top